Clinical Practice on Gout Management Among Filipino General Care Practitioners


Title: Evidence-based practice guidelines for gout management is widely available. However, management by general care practitioners is still far from ideal.

Objectives: This study aims to determine the current trends in the management of gout among general care practitioners.

Methodology: Survey questionnaires randomly distributed to the general membership of the Philippine College of Physicians (PCP) and the Philippine Academy of Family Physicians (PAFP).

Results: A total of 390 respondents participated, the majority being females (237, 60.8%) with a mean age of 37.32 + 10.22 (20-75) years, half of them holding practice within Metro Manila. The duration of practice was divided into four categories: 72 (18.5%) had <1 year of practice, 138 (35.4%) had 1-5 years of practice, 64 (16.4%) 5-10 years, and 116 (29.7%) had >10 years of practice. Two hundred and twelve (54%) respondents did not attend gout continuing medical education (CME) activities. More than half agreed with synovial fl uid examination to confi rm gout diagnosis in patients with acute monoarthritis. During a gout fl are, 60.5% preferred colchicine while 15.8% prescribed uratelowering therapies. Colchicine dosing 3x daily was preferred in 30.3% while 17.4% advocated hourly dose until GI toxicity. Urate-lowering therapies (ULT) 1-2 weeks after the gout fl are was preferred by 43.3% while 37.4% opted to give it until serum uric acid level (SUA) normalized before discontinuation. Most respondents (60%) chose prophylactic colchicine when starting ULTs. Half of the respondents (49.7%) aimed for SUA level of 6 mg/dL. In chronic tophaceous gout, 46.9% targeted a higher value of 5 mg/dL.

Conclusion Though gout management has improved among general care practitioners, there were still observed inconsistencies and heterogeneous patterns of practice in the community.

Keywords: gout survey, adherence to gout guidelines, Filipino.

  1. Li-Yu J.  Relationship of Gout and Hyperuricemia in Cardiovascular and Renal Morbidity: 2003 National Nutrition and Health Survey (NNHeS), Phil J. Internal Medicine 2008;46 (Nov-Dec): 279-285
  2. Zhu Y, Pandya BJ, Choi HK.  Prevalence of Gout and Hyperuricemia in the US General population. The National Health and Nutrition Examination Survey 2007-2008. Arthritis & Rheumatism 2011;63(10):3136-3141. Available from: doi:10.1002/art.30520
  3. Prasad P and Krishnan E.  Filipino Gout: A Review.  Arthritis Care and Research 2014;66(3):337-343.doi:10.1002/acr.22118
  4. Torralba TP and Bayani-Sioson P. The Filipino and Gout. Seminars in Arthritis and Rheumatism 1975; 4: 307-320
  5. Becker MA, Schumacher Jr HR, MacDonald PA, et al. Clinical Efficacy and Safety of Successful Longterm Urate-Lowering with Febuxostat or Allopurinol in Subjects with Gout.  J Rheumatol 2009; 36(6); 1273-82. Available from: doi:10.3899/jrheum.080814
  6. Hamijoyo L, Li-Yu J, Torralba T.  A survey on the Clinical management of Gout among Filipino Physicians, Phil J Internal Medicine  2008; 46(Mar-Apr); 51-55
  7. Li-Yu J, Salido EO, Manahan S, Lichauco JJ, Lorenzo, JP, Torralba KT et al. Philippine Practice Guidelines for the Management of Gout, Phil J Internal Medicine 2008:46;165-173
  8. Doherty M, Bardin T, Pascual E.  International Survey on the Diagnosis and management of Gout. Ann Rheum Dis 2007;66(12):1685–1686. Available from: doi:10.1136/ard.2007.071530.
  9. Pascual e, Silvera F, Andres M. Synovial Fluid Analysis for Crystals, Curr Opin Rheumatol 2011;23(2):161-9. Available from: doi:10.1097/BOR.0b013e328343e458.
  10. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 Updated EULAR evidence-based recommendations for the management of Gout. Ann Rheum Dis 2016(0):1-14. Available from:doi:1136/annrheumdis-2016-209707.
  11. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: Systematic NonPharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research 2012:64(10); 1431-46. Available from: doi:10.1002/acr.21772.
  12. Shekelle PG, Newberry SJ, Fitzgerald JD, Motala A, O’Hanlon CE, Tariq A, et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2017;166(1):37-51.Available from:doi:10.7326/M16-0461.
  13. Wortmann RL and Kelley WN. Gout and hyperuricemia. In Harris ED, Budd RC, Firestein GS et al. Editors. Kelley’s textbook of rheumatology. 7th ed. Elsevier Saunders. Philadelphia 2005: 1402-1429
  14. Reginato A. Gout and other crystal arthropathies. In: Kasper DL, Fauci AS, Braunwald E, Hauser SL, et al. Editors. Harrison’s principles of internal medicine. 16th ed. McGraw-Hill companies. New York 2005: 2046-2050
  15. Terkeltaub,RA. Gout. New Engl J Med 2003;349(17):1647-1655. Available from: doi:10.1056/NEJMcp030733.
  16. Xin Feng, Yao Li, Wei Gao.  Significance of the Initiation Time of Urate-Lowering therapy in Gout Patients: A Retrospective Research, Joint Bone Spine 2015;82(6): 428-31. Available from:
  17. Hill EM, Sky K, Sit M, et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015(3);21:120–5. Available from: doi:10.1097/RHU.0000000000000235.
  18. Perez-Ruiz F. Treating to Target: a Strategy to Cure Gout. Rheumatology 2009;48(suppl 2):ii9-ii14. Available from: doi:10.1093/rheumatology/kep087
  19. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society of Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2007(8); 46:1372-1374. Available from: doi:
  20. Perez-Ruiz F, Naredo E. Imaging modalities and monitoring measures of gout. Curr Opin Rheumatol 2007;19(2):128–33. Available from: doi:10.1097/BOR.0b013e32801450b7.
  21. Harrold L, Mazor K, Negron A et al, Primary Care Providers' Knowledge, Beliefs and Treatment Practices of Gout: Results of Physician Questionnaire. Rheumatology (Oxford) 2013(9); 52:1623-29. Available from: doi:

Articles related to the one you are viewing

There are currently no results to show, please try again later

CC BY: Open Access Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit